These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 28129775)

  • 1. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.
    Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y
    World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.
    Stojsic J; Stankovic T; Stojkovic S; Milinkovic V; Dinic J; Milosevic Z; Milovanovic Z; Tanic N; Bankovic J
    Exp Mol Pathol; 2015 Feb; 98(1):27-32. PubMed ID: 25449334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
    Cho HJ; Kim HR; Park YS; Kim YH; Kim DK; Park SI
    Surg Oncol; 2015 Dec; 24(4):329-34. PubMed ID: 26690822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.
    Xie Q; Liang J; Rao Q; Xie X; Li R; Liu Y; Zhou H; Han J; Yao T; Lin Z
    Ann Surg Oncol; 2016 Jan; 23(1):163-70. PubMed ID: 25916979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
    Shimizu K; Yukawa T; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M
    World J Surg Oncol; 2015 Feb; 13():21. PubMed ID: 25888998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
    Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
    Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HSP90B1 overexpression predicts poor prognosis in NSCLC patients.
    Xu Y; Chen Z; Zhang G; Xi Y; Sun R; Wang X; Wang W; Chai F; Li X
    Tumour Biol; 2016 Oct; 37(10):14321-14328. PubMed ID: 27599983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
    Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CMTM1_v17 is a novel potential therapeutic target in breast cancer.
    Wang J; Zhang G; Zhang Y; Luo Y; Song Q; Qiu X; Mo X; Wang L
    Oncol Rep; 2014 Nov; 32(5):1829-36. PubMed ID: 25175386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in non-small cell lung cancer.
    Chen X; Qian D; Cheng J; Guan Y; Zhang B; Ding X; Zeng J; Chen X; Er P; Zhang F; Zhao N; Chen X; Zhao L; Yuan Z; Pang Q; Wang P
    Tumour Biol; 2016 Oct; 37(10):13489-13498. PubMed ID: 27465554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serpin b3 is associated with poor survival after chemotherapy and is a potential novel predictive biomarker in advanced non-small-cell lung cancer.
    Urquhart G; Kerr KM; Nicolson M; Loo PS; Sharma R; Shrimali R; Petty RD
    J Thorac Oncol; 2013 Dec; 8(12):1502-9. PubMed ID: 24389432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy.
    Lee SH; Choi SI; Lee JS; Kim CH; Jung WJ; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kang KH; In KH
    Cancer Res Treat; 2017 Jan; 49(1):141-149. PubMed ID: 27188201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
    J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
    AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expression of plakoglobin is a potential prognostic biomarker for patients with surgically resected lung adenocarcinoma.
    He X; Zhou T; Yang G; Fang W; Li Z; Zhan J; Zhao Y; Cheng Z; Huang Y; Zhao H; Zhang L
    Oncotarget; 2016 Mar; 7(12):15274-87. PubMed ID: 26933815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
    Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
    Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CMTM1-v17, a new potential corepressor of androgen receptor].
    Zhu BM; Li T; Zhou YL; Song QS; Wang L
    Beijing Da Xue Xue Bao Yi Xue Ban; 2007 Aug; 39(4):388-93. PubMed ID: 17657266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
    Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
    Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.